Managed Care - May 2008 - (Page 27) Treat today with NAMENDA Proven efficacy with excellent tolerability n Improves function, delays onset of behavioral symptoms, and provides benefits in cognition1-3 n Excellent safety and tolerability with low risk of gastrointestinal side effects may improve therapy persistence4,5 n Proven to reduce caregiving time, cost and caregiver distress3,6,7 n Proven effective first-line and in combination with an acetylcholinesterase inhibitor1,2 Broad patient access—covered on 98% of Medicare Part D formularies4 NAMENDA® (memantine HCI) is indicated for the treatment of moderate to severe Alzheimer’s disease. NAMENDA is contraindicated in patients with known hypersensitivity to memantine HCl or any excipients used in the formulation. The most common adverse events reported with NAMENDA vs placebo (≥5% and higher than placebo) were dizziness, confusion, headache, and constipation. In patients with severe renal impairment, the dosage should be reduced. References: 1. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ, for the Memantine Study Group. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348:1333-1341. 2. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, for the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317-324. 3. Cummings JL, Schneider E, Tariot PN, Graham SM, for the Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67:57-63. 4. Data on file. Forest Laboratories, Inc. 5. NAMENDA® (memantine HCl) Prescribing Information. Forest Pharmaceuticals, Inc., St Louis, Mo. 6. Wimo A, Winblad B, Stöffler A, Wirth Y, Möbius HJ. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics. 2003;21:327-340. 7. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-BEST Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14:135-146. For more details, please visit www.namenda.com. Please see brief summary of Prescribing Information on the adjacent page. © 2008 Forest Laboratories, Inc. 62-1012588R 03/08 http://www.namenda.com http://www.namenda.com
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.